A Phase 3 interventional study of SB12 (proposed eculizumab biosimilar) and Soliris (eculizumab) in Paroxysmal Nocturnal Hemoglobinuria, sponsored by Samsung Bioepis Co., Ltd.. Completed at 27 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-03-26.
Sponsored by Samsung Bioepis Co., Ltd. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies testing eculizumab in Hemoglobinuria, Paroxysmal — none open to participants now, none under way, none of them phase 3. eculizumab · Hemoglobinuria, Paroxysmal.
Among the 18 studies testing eculizumab in Hemoglobinuria, Paroxysmal, this one is the 7th largest by enrollment, is one of 3 that started in 2019, is one of 14 in phase 3, and was the 10th registered.
191 studies on the registry are indexed under Hemoglobinuria, Paroxysmal; 49 are open to participants now.
Browse Hemoglobinuria, Paroxysmal studies →None of the 18 studies testing eculizumab in Hemoglobinuria, Paroxysmal is open now. The open studies under Hemoglobinuria, Paroxysmal, anywhere →
eculizumab: first FDA approval 2007 (SOLIRIS), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 30 Hemoglobinuria, Paroxysmal studies recruiting now, 14 (47%) set no upper age limit and 12 (40%) stop at 75 or younger; 12 take children under 18; 4 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 3 started in 2019.
This study's enrollment of 50 is above the median of 33 across 150 interventional studies indexed under Hemoglobinuria, Paroxysmal.
Median enrollment 37 across the 18 interventional studies. Of the 18 that completed or were terminated, 9 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
16 of 18 have an industry lead sponsor. The 8 most frequent:
Samsung Bioepis Co., Ltd. is the lead sponsor of 33 studies on the registry; 2 are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 3 (50%) have results posted.
Samsung Bioepis Co., Ltd. has 1 study filed under Hemoglobinuria, Paroxysmal — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 18 studies testing eculizumab in Hemoglobinuria, Paroxysmal, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a randomised Phase III, double-blind, multicentre, cross-over study to compare the efficacy, safety, pharmacokinetics, and immunogenicity between SB12 and Soliris® in subjects with PNH.
Subjects will be randomised in a 1:1 ratio to either treatment sequence. Subjects randomly assigned to treatment with SB12 or Soliris® will receive 600 mg of eculizumab IV every week for first 4 weeks (initial phase) and 900 mg for the fifth week, followed by 900 mg every 2 weeks until Week 52. Subjects who are randomised to initially receive SB12 will be switched to receive Soliris® and subjects who are randomised to initially receive Soliris® will be switched to receive SB12 at Week 26.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects who are randomised to initially receive SB12 will be switched to receive Soliris® at Week 26
Drug: SB12 (proposed eculizumab biosimilar) · Drug: Soliris (eculizumab)
Subjects who are randomised to initially receive Soliris® will be switched to receive SB12 at Week 26
Drug: SB12 (proposed eculizumab biosimilar) · Drug: Soliris (eculizumab)
600 mg IV every week for first 4 weeks and 900 mg for the fifth week, followed by 900 mg every 2 weeks thereafter
600 mg IV every week for first 4 weeks and 900 mg for the fifth week, followed by 900 mg every 2 weeks thereafter
Lactate Dehydrogenase (U/L) at Week 26
Time frame: Week 26
Time-adjusted AUEC of LDH From Week 14 to Week 26 and From Week 40 to Week 52
Time frame: From Week 14 to Week 26 and from Week 40 to Week 52
| Milestone | Soliris to SB12 | SB12 to Soliris |
|---|---|---|
| Started | 25 | 25 |
| Completed | 23 | 23 |
| Not completed | 2 | 2 |
| Withdrew: Death | 1 | 0 |
| Withdrew: Adverse event | 1 | 1 |
| Withdrew: Pregnancy | 0 | 1 |
| Milestone | Soliris to SB12 | SB12 to Soliris |
|---|---|---|
| Started | 23 | 23 |
| Completed | 23 | 23 |
| Not completed | 0 | 0 |
| U/L | SB12 | Soliris |
|---|---|---|
| Lactate Dehydrogenase (U/L) at Week 26 | 284.20 ± 456.73 | 249.72 ± 103.67 |
| U/L | SB12 | Soliris |
|---|---|---|
| Time-adjusted AUEC of LDH From Week 14 to Week 26 and From Week 40 to Week 52 | 279.65 ± 325.37 | 258.73 ± 95.09 |
Collected over From the time of signing the informed consent form until Week 58 (EOS Visit) or ET Visit. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| SB12 | 0/47 (0%) | 3/47 (6.4%) | 18/47 (38.3%) |
| Soliris | 1/47 (2.1%) | 2/47 (4.3%) | 11/47 (23.4%) |
| Event | SB12 | Soliris |
|---|---|---|
| Hand fractureInjury, poisoning and procedural complications | 1/47 | 0/47 |
| HaemolysisBlood and lymphatic system disorders | 1/47 | 0/47 |
| Infusion site hypersensitivityGeneral disorders | 0/47 | 1/47 |
| Portal vein thrombosisHepatobiliary disorders | 0/47 | 1/47 |
| CellulitisInfections and infestations | 0/47 | 1/47 |
| Wound infection bacterialInfections and infestations | 1/47 | 0/47 |
| Event | SB12 | Soliris |
|---|---|---|
| Corona virus infectionInfections and infestations | 8/47 | 3/47 |
| HaemoglobinuriaRenal and urinary disorders | 8/47 | 2/47 |
| DiarrhoeaGastrointestinal disorders | 4/47 | 2/47 |
| Alanine aminotransferase increasedInvestigations | 3/47 | 2/47 |
| HeadacheNervous system disorders | 2/47 | 3/47 |
| HypertensionVascular disorders | 3/47 | 0/47 |
| Age, Continuous(years) | Soliris to SB12 | SB12 to Soliris | Total |
|---|---|---|---|
| Mean | 36.3 ± 13.67 | 40.0 ± 13.44 | 38.1 ± 13.55 |
| Sex: Female, Male(Participants) | Soliris to SB12 | SB12 to Soliris | Total |
|---|---|---|---|
| Female | 14 | 8 | 22 |
| Male | 11 | 17 | 28 |
| Race (NIH/OMB)(Participants) | Soliris to SB12 | SB12 to Soliris | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 12 | 15 | 27 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 11 | 7 | 18 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 2 | 3 | 5 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Aug 2019 to primary completion in Sep 2021, 25 months.
Results were first posted in Mar 2024, 2 years 6 months after primary completion.
Of 35 industry-sponsored phase 3 interventional studies under Hemoglobinuria, Paroxysmal, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 41. This study's 25 months is close to that.
Counting every sponsor, half of 35 studies reached it within 23 months; a quarter within 15 and three quarters within 41.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Eculizumab